Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Monte Rosa Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update ● On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023 ● Received Orphan Drug Designation from the U.S. Food and Drug Administration for MRT-2359 for the treatment of small cell lung cancer ● Announced development candidate MRT-6160, a novel, highly selective molecular glue degrader of VAV1, with IND submission expected 1H 2024 ● Strong cash position expected to sustain operations into 2025 and enable advancement of pipeline of novel molecular glue degraders BOSTON, Mass., August 10, 2023 –"
05/11/2023 8-K Quarterly results
Docs: "Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update • On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023 • Cash runway into 2025 supports operations and advancement of pipeline of novel molecular glue degraders to key inflection points BOSTON, Mass., May 11, 2023 –"
03/16/2023 8-K Investor presentation, Quarterly results
Docs: "Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update • Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing • Disclosure of initial data from Phase 1 arm of study expected in second half of 2023 • MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer with L-MYC or N-MYC expression • Nomination of multiple development candidates anticipated in 2023 • Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025 BOSTON, March 16, 2023 –",
"NE NCI-H2405 NCI-H1693 NCI-H810 NCI-H1770"
08/11/2022 8-K Quarterly results
Docs: "Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates – Submitted Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – – Cash Runway into Late 2024 with $299.5 Million in Cash, Cash Equivalents, Restricted Cash and Marketable Securities as of June 30, 2022 – BOSTON, August 11, 2022"
05/11/2022 8-K Quarterly results
03/29/2022 8-K Quarterly results
Docs: "Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates – Company on Track for Mid-year Filing of Investigational New Drug Application for Lead Candidate MRT-2359 – – Progressed NEK7 and CDK2 Molecular Glue Degrader Programs into Lead Optimization – – Year-end Cash and Cash Equivalents Expected to Provide Runway into Late 2024 – BOSTON, March 29, 2022"
08/12/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy